# New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)

> **NCT00035269** · PHASE3 · COMPLETED · sponsor: **Pfizer** · enrollment: 230 (actual)

## Conditions studied

- Pneumonia, Pneumococcal
- Community Acquired Infections
- Gram-positive Bacterial Infections

## Interventions

- **DRUG:** Antibiotic

## Key facts

- **NCT ID:** NCT00035269
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2001-12
- **Primary completion:** —
- **Final completion:** 2003-05
- **Target enrollment:** 230 (ACTUAL)
- **Last updated:** 2011-04-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00035269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00035269, "New Antibiotic to Treat Patients With Community-acquired Pneumonia Due to a Specific Bacteria (S. Pneumoniae Pneumonia)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00035269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*